Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Seller To Pump Funds Into India’s Fortis, Religare

This article was originally published in PharmAsia News

Executive Summary

The seller of Ranbaxy Laboratories plans to use some of the proceeds from Japan's Daiichi Sankyo to make India's Religare and Fortis health care companies industry leaders in India. Ranbaxy CEO Malvinder Singh said that for the next several years, Ranbaxy would focus on becoming the No. 1 health care company in the country. In the long run, he said, the plan is to phase in Fortis as an international company. He rejected speculation Fortis would be combined with the Anil Ambani group. (Click here for more

You may also be interested in...



Bharat Biotech To Make GSK’s Malaria Vaccine For WHO

GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs

Irish Ad Code Covers OTC Devices And Herbals For First Time

Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.

2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry

HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe. 

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel